

NCT ID	NCT05609370
Title	A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2022-11-08
Location	Alaska, United States Arizona, United States California, United States Florida, United States Indiana, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nevada, United States New Mexico, United States New York, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Australia China Puerto Rico
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Bevacizumab, capecitabine, LBL-007, Tislelizumab
Tags	MSS/ MMRp
NCT ID	NCT04085185
Title	A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors
Phase	Phase 1
Date Added	2019-09-11
Location	China
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	IBI110, IBI110+ Sintilimab, IBI110, Sintilimab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04009681
Title	A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2019-07-05
Location	Arizona, United States Colorado, United States Florida, United States Tennessee, United States Texas, United States Argentina Australia Chile Singapore Spain
Prior IO Allowed	No

CRC-directed	No
Status	Active, not recruiting
Drugs	anti-EGFR antibody, Checkpoint inhibitor, THOR-707
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05653882
Title	A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
Phase	Phase 1
Date Added	2022-12-16
Location	California, United States Connecticut, United States Florida, United States Massachusetts, United States Michigan, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Tennessee, United States Virginia, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05491317
Title	A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2022-08-08
Location	France
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06513221
Title	A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab
Phase	
Date Added	2024-07-22
Location	
Prior IO Allowed	No
CRC-directed	Yes
Status	
Drugs	
Tags	MSS/ MMRp
NCT ID	NCT03981146
Title	A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
Phase	Phase 2
Date Added	2019-06-10

Location	United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Nivolumab, Opdivo
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT05205330
Title	A Phase Ib/Ila Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients
Phase	Phase 2
Date Added	2022-01-25
Location	Italy
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	AGEN2034, Balstilimab, CR6086
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT04550897
Title	A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients
Phase	Phase 1
Date Added	2020-09-16
Location	Norway
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	BM7PE
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT06508307
Title	A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
Phase	Phase 1
Date Added	2024-07-18
Location	China
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp